#None #pharmaceuticals #Norgine #Theravia

Norgine and Theravia: A New Chapter in Pharmaceutical Innovation

In a significant development for the global pharmaceutical landscape, Norgine has successfully finalized its acquisition of Theravia, an international company known for its focus on therapies aimed at patients grappling with rare and debilitating conditions. This strategic move is seen as a pivotal step toward fulfilling Norgine's commitment to delivering transformative medicines to patients with pressing medical needs.

The announcement came on August 14, 2025, marking a notable milestone for Norgine as it continues on its trajectory of growth in the pharmaceutical sector. Janneke van der Kamp, CEO of Norgine, expressed enthusiasm about integrating Theravia into their operations. “We are pleased about the successful closing of this acquisition as the addition of Theravia to our company further enhances our expertise in and growing portfolio of rare disease medicines,” said van der Kamp.

The acquisition of Theravia, now a wholly owned subsidiary of Norgine, signifies not only an expansion of Norgine's product offerings but also an enhancement of its capabilities to reach patients with rare diseases that historically suffer from high unmet needs.

This move aligns well with Norgine’s growth strategy, which is increasingly focused on bolstering its portfolio of products that cater to specific health challenges. Norgine aims to leverage its established operational excellence to facilitate a seamless integration process, aligning systems and teams to foster unified operations.

With annual revenues exceeding €550 million and a legacy spanning over 120 years, Norgine has built a reputation as a prominent player in specialty pharmaceuticals and consumer healthcare. Their distinctive integrated approach encompasses strong commercial capabilities, robust supply networks, and extensive medical, regulatory, and clinical expertise. This integration is crucial for ensuring that the innovative medicines, which are central to Theravia's mission, reach the broadest possible patient population.

As Norgine embarks on this new chapter, the company is poised to enhance its service in markets across Western Europe, Australia, and New Zealand. The focus on operational excellence will enable Norgine to carry forward the legacy of innovation it has established over the decades. Their commitment to addressing rare diseases sets a clear path toward making impactful contributions to patients who are in dire need of new treatment options.

Looking ahead, Norgine is dedicated to ensuring that the transition is smooth and efficient, maximizing the potential of Theravia’s offerings. The integration process will be crucial in maintaining the high standards that both companies uphold in the pharmaceutical industry.

As a nimble and innovative entity, Norgine's strategic acquisition of Theravia highlights not only its commitment to pharmaceutical excellence but also reflects its proactive approach to addressing critical healthcare challenges. In a world where rare diseases often go underfunded and overlooked, Norgine's action serves as a beacon of hope for patients and healthcare professionals alike, illuminating a path toward improved treatment solutions.

This acquisition has been welcomed with optimism, and both Norgine and Theravia stand to benefit from the combined expertise and resources, creating a formidable force in the pharmaceutical field capable of making substantial advances in medical care and accessibility.

With this acquisition, Norgine is not only bridging gaps in healthcare but also reinforcing its mission of empowering patients through groundbreaking medicinal advancements. As they embark on this journey together, the promise of reaching more patients with high unmet medical needs is now more attainable than ever before.